Simulations Plus

Simulations Plus Equity

The The Equity of Simulations Plus (SLP) as of Sep 27, 2026 is 124.80 M USD. In the previous year, The Equity was 182.43 M USD — a change of -31.59% (lower).

Equity

124.80 MUSD

YoY

-31.59%

Last updated:

In 2026, Simulations Plus's equity was 124.80 M USD, a -31.59% increase from the 182.43 M USD equity in the previous year.

The Simulations Plus Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
31.92 M USD
Jan 1, 2019
37.68 M USD
Jan 1, 2020
156.04 M USD
Jan 1, 2021
165.78 M USD
Jan 1, 2022
178.25 M USD
Jan 1, 2023
170.03 M USD
Jan 1, 2024
182.43 M USD
Jan 1, 2025
124.80 M USD
The Simulations Plus Equity history
YEAREquityYoY
124.80 MUSD-31.59%
182.43 MUSD+7.29%
170.03 MUSD-4.61%
178.25 MUSD+7.52%
165.78 MUSD+6.25%
156.04 MUSD+314.09%
37.68 MUSD+18.04%
31.92 MUSD+23.71%
25.80 MUSD+13.51%
22.73 MUSD+16.39%
19.53 MUSD+26.54%
15.44 MUSD—
Access this data via the Eulerpool API

Simulations Plus Stock analysis

What does Simulations Plus do? Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health. The translation of the text is: "Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health." Simulations Plus is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Simulations Plus's Equity

Simulations Plus's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Simulations Plus's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Simulations Plus's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Simulations Plus's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Simulations Plus’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Simulations Plus stock

The Equity of Simulations Plus is 124.80 M USD in 2026.

The Equity of Simulations Plus changed from 182.43 M USD to 124.80 M USD, representing a -31.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Simulations Plus since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Simulations Plus historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Simulations Plus

All Key Metrics — Simulations Plus